Sign In
Buy NVAX
$10.20
-0.0100 (-0.0979%)
At Close: Jun 03, 2026
Analysts Think These Stocks Could More Than Double in Value
07:46am, Friday, 23'rd May 2025
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
08:15am, Wednesday, 21'st May 2025
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the o
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
04:34pm, Tuesday, 20'th May 2025
The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.
S&P 500 INDEX (SPX) Live: Markets Pare Losses in Face of Credit Downgrade
01:30pm, Tuesday, 20'th May 2025
Live Updates Live Coverage Has Ended Jamie Dimon on the Risk of Inflation and Deflation 3:23 pm by Gerelyn Terzo The markets have recouped most of their losses, with the SPX now down a modest 0.03%. J
Top Stock Movers Now: Tesla, AutoZone, Novavax, and More
12:15pm, Monday, 19'th May 2025
U.S. equities were down at midday, while the yield on the 10-year Treasury jumped, as the market reacted to Moody's downgrading the U.S. debt rating. The Dow Jones Industrial Average, S&P 500, and Nas
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
10:45am, Monday, 19'th May 2025
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
Novavax Stock Soars on FDA Approval for COVID Vaccine
10:33am, Monday, 19'th May 2025
Biotech stock Novavax Inc (NASDAQ:NVAX) is skyrocketing today, up 26% at $8.48 at last glance, after the U.S. Food & Drug Administration (FDA) approved the company's COVID-19 vaccine.
Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.
09:27am, Monday, 19'th May 2025
Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.
Novavax shares surge 26% after FDA grants conditional approval for Covid vaccine
09:24am, Monday, 19'th May 2025
Novavax, Inc. (NASDAQ:NVAX) shares jumped 26% in premarket trading on Monday after the U.S. Food and Drug Administration granted full approval for its COVID-19 vaccine, though with narrower eligibili
Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine
07:16am, Monday, 19'th May 2025
Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine from the U.S. health regulator, albeit with new conditions.
U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
07:00am, Monday, 19'th May 2025
Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. Biologics License Application approval triggers $175 million Sanofi milestone payment, with addition
FDA approves Novavax COVID vaccine with new conditions
10:26pm, Saturday, 17'th May 2025
The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine.
Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)
10:46pm, Wednesday, 14'th May 2025
Novavax, Inc. (NASDAQ:NVAX ) BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ET Company Participants John Jacobs - President and CEO Jim Kelly - CFO Ruxandra Draghia-Akli - EVP, Head,
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Tuesday, 13'th May 2025
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat
12:45pm, Monday, 12'th May 2025
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven
